Abstracts tagged "Systemic sclerosis"

Abstract Number: 0396 • ACR Convergence 2020
Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase 3 Trial
Dinesh Khanna¹, Celia J. F. Lin², Helen Spotswood³, Jeffrey Siegel², Daniel Furst*⁴ and Christopher Denton⁵, ¹University of Michigan, Ann Arbor, MI, ²Genentech, South San Francisco, CA, ³Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁴Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ⁵University College London, London, United Kingdom
Background/Purpose: The anti–interleukin-6 (IL-6) receptor-α antibody tocilizumab (TCZ) demonstrated skin score improvement and forced vital capacity (FVC) preservation in patients with systemic sclerosis (SSc) in…
Abstract Number: 1070 • ACR Convergence 2020
Scleromyositis Is Associated with Distinct Muscle Vasculopathic Features
Océane Landon-Cardinal¹, Valérie Leclair², Yves Troyanov³, Alain Meyer⁴, Sabrina Hoa¹, Josiane Bourré-Tessier¹, Valérie Nadon⁵, Julie Drouin⁶, Jason Karamchandani⁷, Erin O'Ferrall⁸, Minoru Satoh⁹, Marvin Fritzler¹⁰, Jean-Luc Senécal¹, Marie Hudson² and Benjamin Ellezam¹¹, ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ⁴Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁵Division of Rheumatology, Hôpital Notre-Dame, Montreal, Québec, Canada, Montréal, QC, Canada, ⁶Division of Rheumatology, Centre hospitalier régional de Trois-Rivières, Trois-Rivières, QC, Canada, ⁷Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁸Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁹Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis (AIM) associated with features of systemic sclerosis (SSc). Muscle biopsy studies are sparse and have…
Abstract Number: 1526 • ACR Convergence 2020
Single Cell Analysis of Skin and Blood of Scleroderma Patients Towards Identification of New Disease Mechanisms, Prognostic Biomarkers and Potential Therapeutic Targets
Chamutal Gur¹, Postil 158626², Hagit Peleg³, Suhail Aamar³, Fadi Kharouf³, Anat Elazary³, Yolanda Braun-Moscovici Braun-Moscovici⁴, Shuang-Yin Wang⁵ and Ido Amit⁵, ¹Hadassah Medical Center, Hebrew University, Laboratory for Immuno-Genomics, Weizmann Institute of Science, Jerusalem, Israel, ²Rambam Health Care Campus, Technion-Israeli Institute of Technology, Kiriat Mozkin, HaZafon, Israel, ³Hadassah Medical Center, Jerusalem, Israel, ⁴Rambam Health Care Campus, Technion-Israeli Institute of Technology, Haifa, Israel, ⁵Laboratory for Immuno-Genomics, Weizmann Institute of Science, Rehovot, Israel
Background/Purpose: Systemic sclerosis (SSc) is characterized by fibrosis, microangiopathy and immune dysregulation. Despite many years of research, the pathogenesis of SSc is poorly understood; there…
Abstract Number: 0397 • ACR Convergence 2020
Assessing Adherence to Screening of Systemic Sclerosis-Related Lung Disease
Matthew Herrmann¹ and Zineb Aouhab¹, ¹Loyola University Medical Center, Maywood, IL
Background/Purpose: Feared complications of systemic sclerosis (SSc) affect the pulmonary system, with pulmonary hypertension and interstitial lung disease being common causes of mortality. Baseline and…
Abstract Number: 1128 • ACR Convergence 2020
The Diagnosis of Systemic Sclerosis as a Traumatic Experience: Patients’ Reactions to the Diagnostic Process
Fennell Patricia¹, Lee Shapiro², Nancy Dorr³, Roberta Lukasiewicz⁴, Frank Houser⁵ and Madison Taylor⁶, ¹Albany Health Management Associates, Steffens Scleroderma Foundation, Albany, NY, ²Albany Medical College, Stillwater, NY, ³The College of Saint Rose, Albany, NY, ⁴Steffens Scleroderma Foundation, Albany, NY, ⁵The College of Saint Rose, Nassau, NY, ⁶The College of Saint Rose, Mississauga, ON, Canada
Background/Purpose: Both the process of being diagnosed with a chronic illness and the illness itself can be a traumatizing experience (1). The current study examined…
Abstract Number: 1905 • ACR Convergence 2020
Soluble Guanylate Cyclase Reduced the Gastrointestinal Fibrosis in Bleomycin-induced Mouse Model of Systemic Sclerosis
Yuzuru Yamamoto¹, Takaichi Okano², Takumi Nagamoto², Yoshikazu Fujikawa³, Yoshihide Ichise², Hirotaka Yamada², Ikuko Naka², Yo Ueda⁴, Kengo Akashi⁵, Sho Sendo⁶, Akira Onishi⁵, Jun Saegusa⁷ and Akio Morinobu⁵, ¹Kobe University, Kobe-city, Japan, ²Kobe University, Kobe, Japan, ³Kobe University, Kobe city, Japan, ⁴Kobe UniversityRheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, ⁵Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, ⁶Kobe University, Kobe, ⁷Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune-mediated connective tissue disorder. Although the etiology of the disease remains undermined, SSc is characterized by fibrosis and…
Abstract Number: 0398 • ACR Convergence 2020
Chest CT Ordering Practices at Expert Scleroderma Centers in the United States
Elana Bernstein¹, John VanBuren², Shervin Assassi³, Flavia Castelino⁴, Lorinda Chung⁵, Chase Correia⁶, Luke Evnin⁷, Tracy Frech⁸, Emily Startup², Jessica Gordon⁹, Faye Hant¹⁰, Laura Hummers¹¹, Nora Sandorfi¹², Ami Shah¹³, Victoria Shanmugam¹⁴, Virginia Steen¹⁵ and Dinesh Khanna¹⁶, ¹Columbia University, New York, NY, ²University of Utah, Salt Lake City, UT, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ⁶Northwestern University, Chicago, IL, ⁷Scleroderma Research Foundation, Brisbane, CA, ⁸University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Johns Hopkins Univerisity, Ellicott City, MD, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Johns Hopkins University School of Medicine, Ellicott City, MD, ¹⁴The George Washington University, Washington, DC, ¹⁵Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although pulmonary function tests (PFTs) are commonly used…
Abstract Number: 1170 • ACR Convergence 2020
Exploring the Use of Von Willebrand Factor as a Disease Biomarker in a Cohort of Patients with Juvenile Scleroderma: A Pilot Study
Natalia Vasquez-Canizares¹, Beamon Agarwal², Tamar Rubinstein³, Dawn Wahezi¹ and Morayma Reyes-Gil¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²GenomeRxUS LLC, Clifton Heights, PA, ³Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY
Background/Purpose: Juvenile Scleroderma (JScl) is a heterogenous disease characterized by autoimmunity, vasculopathy, and fibrosis. Morbidity and mortality remain high in part due to the continuing…
Abstract Number: 1907 • ACR Convergence 2020
DNASE1L3 R206C Polymorphism, a Systemic Sclerosis Risk Factor, Causes Impaired Digestion of Genomic DNA in Apoptosis-derived Extracellular Vesicles
Brian Skaug¹, Julio Charles¹, Jacob Couturier², Dorothy Lewis², Maureen Mayes³ and Shervin Assassi³, ¹University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²University of Texas Houston McGovern Medical School, Division of Infectious Diseases, Houston, TX, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Two independent studies on genetic risk factors for systemic sclerosis (SSc) identified a polymorphism of Deoxyribonuclease 1-like 3 (DNASE1L3) associated with increased SSc risk. …
Abstract Number: 0401 • ACR Convergence 2020
Prevalence and Characteristics of Systemic Sclerosis Patients Fulfilling the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus
Ronald Bass¹, Duncan Moore² and Virginia Steen², ¹Georgetown University School of Medicine, Washington, DC, ²Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC
Background/Purpose: Literature describing the overlap syndrome of SSc and SLE is limited and has employed a range of case definitions. Our study sought to use…
Abstract Number: 1377 • ACR Convergence 2020
Raynaud’s Phenomenon and Systemic Sclerosis in Post-9/11 Deployed Veterans Receiving Care Veterans Health Administration Care
Tracy Frech¹, Maureen Murtaugh¹, Megan Amuan² and Mary Jo Pugh¹, ¹University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ²Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: The purpose of this project was to describe Raynaud's phenomenon (RP), very early diagnosis of systemic sclerosis (VEDOSS), and systemic sclerosis (SSc) in Veterans…
Abstract Number: 1908 • ACR Convergence 2020
Establishment of iPSc and Differentiated Endothelial Cells of Systemic Sclerosis Associated Pulmonary Arterial Hypertension ; Functional and Molecular Analysis
Yuki Kudo¹, Masaru Kato², Yuhei Shibata¹, Michihito Kono², Yuichiro Fujieda², Olga Amengual², Kenji Oku² and Tatsuya Atsumi³, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) occurs either primarily or in association with other diseases such as connective tissue diseases. PAH associated with systemic sclerosis (SSc-PAH)…
Abstract Number: 0913 • ACR Convergence 2020
Systemic Sclerosis Portends a Higher Risk of Conduction and Rhythm Disorders at Diagnosis and During Disease Course: Results from a US Population Based Study
Yasser Radwan¹, Reto Kurmann², Avneek Singh Sandhu³, Edward El-Am⁴, Cynthia Crowson², Eric Matteson⁵, Thomas Osborn², Kenneth Warrington⁶, Rekha Mankad² and Ashima Makol², ¹Mayo Clinic, Rochester, Minnesota, USA, Lansing, MI, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Mayo Clinic, Rochester, Minnesota, USA, Dayton, OH, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, MN, ⁶Mayo Clinic, Rochester, MN
Background/Purpose: Cardiac involvement, including electrocardiogram (ECG) abnormalities, is associated with worse prognosis in systemic sclerosis (SSc). We studied the incidence, risk factors and outcomes of…
Abstract Number: 1379 • ACR Convergence 2020
Clinical Outcomes Among Participants with Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Series
Robyn Domsic¹, Lorinda Chung², Jerry Molitor³, Robert Spiera⁴, Bradley Bloom⁵, Barbara White⁶ and Quinn Dinh⁶, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ³University of Minnesota, Minneapolis, MN, ⁴Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁵Corbus Pharmaceuticals Inc, Norwood, MA, ⁶Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Patients with systemic sclerosis (SSc) may be at increased risk for severe outcomes with COVID-19, given the high rate of immunosuppressive medication use, underlying…
Abstract Number: 1909 • ACR Convergence 2020
High-density Proteomic Analysis of Skin Blister Fluid and Plasma in Systemic Sclerosis Identifies Local and Systemic Differences for Key Proteins
Kristina Clark¹, Corrado Campochiaro², Eszter Csomor³, Adam Taylor³, Katherine Nevin³, Mary Morse³, Voon Ong⁴, Emma Derrett-Smith⁵, Nicolas Wisniacki³, Shaun Flint³ and Christopher Denton¹, ¹University College London, London, United Kingdom, ²Royal Free Hospital NHS trust, London, United Kingdom, ³GlaxoSmithKline, Stevenage, United Kingdom, ⁴UCL, London, United Kingdom, ⁵University College London Division of Medicine, London, United Kingdom
Background/Purpose: Simultaneous analysis of multiple proteins in biological fluids offers insight into the pathogenesis of SSc. Here, we report a proteomic analysis of plasma and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].